| アブストラクト | BACKGROUND/AIM: Concomitant proton pump inhibitor (PPI) and immune checkpoint inhibitor (ICPI) were determined as risk factors of acute kidney injury. To identify the type of PPI associated with ICPI-induced nephritis, we used the Japanese Adverse Drug Event Report database. PATIENTS AND METHODS: ICPIs (nivolumab, pembrolizumab, ipilimumab, atezolizumab, durvalumab, and avelumab) and PPIs (esomeprazole, omeprazole, vonoprazan, rabeprazole, and lansoprazole) were selected as suspected nephritis-inducing drugs. RESULTS: The cases of concomitant use of atezolizumab and rabeprazole, ipilimumab and omeprazole, ipilimumab and lansoprazole, nivolumab and esomeprazole, nivolumab and omeprazole, nivolumab and rabeprazole, nivolumab and lansoprazole, pembrolizumab and esomeprazole, as well as pembrolizumab and lansoprazole had a significantly higher reported odds ratio than monotherapy cases. CONCLUSION: Male patients or patients using ICPIs and PPIs (excluded vonoprazan) concomitantly should be monitored for renal function after chemotherapy. |
|---|
| 投稿日 | 2021/8/20 |
|---|
| 投稿者 | Kato, Koki; Mizuno, Tomohiro; Koseki, Takenao; Ito, Yoshimasa; Hatano, Masakazu; Takahashi, Kazuo; Yamada, Shigeki; Tsuboi, Naotake |
|---|
| ジャーナル名 | In vivo (Athens, Greece) |
|---|
| 組織名 | Department of Clinical Pharmacy, Fujita Health University School of Medicine,;Toyoake, Japan.;Toyoake, Japan; tomohiro.mizuno@fujita-hu.ac.jp.;Department of Nephrology, Fujita Health University School of Medicine, Toyoake,;Japan.;Department of Biomedical Molecular Sciences, Fujita Health University School of;Medicine, Toyoake, Japan. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/34410975/ |
|---|
